Policy & Regulation
-
Drug price negotiations: 5 key dates to watch
As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.
By Kelly Bilodeau • Jan. 23, 2023 -
FDA’s 2022 drug approvals fall short of recent norms
The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.
By Alexandra Pecci • Jan. 19, 2023 -
After ‘limping along,’ Novavax sees a path forward
With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.
By Meagan Parrish • Jan. 18, 2023 -
Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023
As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.
By Michael Gibney • Jan. 5, 2023 -
Opinion
The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences
A preview of the top trends on the minds of industry and market leaders for the new year.
By Taren Grom • Jan. 3, 2023 -
Tracker
The 2023 PharmaVoice Year in Preview
Here’s a look at how industry leaders are navigating the key issues of 2023.
Dec. 12, 2022 -
Q&A
For Duchenne-focused Sarepta, gene therapy is the natural next step
The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.
By Michael Gibney • Dec. 8, 2022 -
Q&A
A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’
The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug.
By Meagan Parrish • Dec. 6, 2022 -
An FDA proposal could make OTC switches easier. Here’s what the industry has to say
How the FDA’s proposal to create a new OTC approval pathway could impact the pharma industry.
By Karissa Waddick • Dec. 5, 2022 -
5 final FDA action dates to watch this year
A potential flurry of regulatory activity could be on the horizon yet this year — and several key drug approvals are at stake.
By Michael Gibney • Dec. 1, 2022 -
10 of our most popular articles in 2022
Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.
By Meagan Parrish • Nov. 30, 2022 -
The next era of Greater Boston’s biotech boom
How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.
By Karissa Waddick , Shaun Lucas , Julia Himmel • Nov. 22, 2022 -
Sponsored by ClinicalMind
Can a formal needs assessment simplify Speaker Bureau compliance?
In the biopharmaceutical industry, phases of innovation and change are often driven by regulatory action.
Nov. 21, 2022 -
Opinion
Why the IRA will drive up the country’s drug bill — not lower it
On the surface, the Inflation Reduction Act is designed to lower drug prices, but its impact on innovation incentives could produce a landscape of new medicines that are costlier for patients.
By John LaMattina • Nov. 14, 2022 -
3 ways pharma can weather a recession
If “winter is coming” in the form of a recession, pharmas can take advantage of an inherent resiliency by crushing these three fundamentals.
By Michael Gibney • Nov. 10, 2022 -
What pharma could gain — or lose — from the midterms
With control of the House and Senate both up for grabs, and potentially leaning Republican, here’s what the midterm elections mean for pharma.
By Karissa Waddick • Nov. 7, 2022 -
Acumen cruises into the fast lane with novel Alzheimer’s treatment
The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.
By Meagan Parrish • Nov. 3, 2022 -
How Europe’s energy crisis is impacting pharma
Inflationary pressures and rising energy costs could further expedite the movement of generics manufacturing from Europe to Asia if governments don’t step in.
By Karissa Waddick • Nov. 2, 2022 -
Riches, rags, riches: Is Biogen the Cinderella of biotechs?
Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.
By Michael Gibney • Oct. 27, 2022 -
Podcast
Woman of the Week: Ironwood Pharmaceuticals’ Diane Stroehmann
The VP of regulatory affairs and global patient safety explains why her line of work lets her do “a little of everything,” and the company’s plans to score a new approval for its blockbuster drug.
By Taren Grom • Oct. 26, 2022 -
Biosimilars will gain ground in 2023 with Humira launches — and that’s just the beginning
In Amgen's 2022 Biosimilars Trend Report, the company tracks the progress and potential of the copycat drugs as they reach a pivotal moment.
By Michael Gibney • Oct. 24, 2022 -
Think your company could be on HHS’ drug price negotiation list? Here’s how to navigate next steps
Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.
By Karissa Waddick • Oct. 18, 2022 -
Making Moves
BIO’s interim CEO and Alvotech’s new chief quality officer could spell big changes for biotech
What these life science organizations’ latest executive-level appointments mean for the industry.
By Karissa Waddick • Oct. 14, 2022 -
Sponsored by GoodRx
Beyond buzzwords: Making a practice of diversity, equity and inclusion
Watch Dr. Preeti Parikh, executive medical director at GoodRx, explain how she sees parallels between her mother’s challenges to promote health equity as a physician, and current diversity, equity, and inclusion (DE&I) challenges in the workplace.
Oct. 10, 2022 -
Q&A
Her antibiotic company failed. Now she’s helping others avoid the same fate.
The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.
By Karissa Waddick • Oct. 6, 2022